Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a P-II Study as 2L Treatment for Advanced Basal Cell Carcinoma
Shots: Shots:
- The ongoing P-II study involves assessing Libtayo (300mg- IV- q3w) for up to 93 wks. or until disease progression- unacceptable toxicity- withdrawal of consent or confirmed complete response in 132 patients with advanced BCC who were intolerant to prior HHI therapy
- The P-II study results: ORR (29% in patients with LA disease) with an estimated DOR exceeding one year in 85% of responders; in a preliminary analysis- ORR (21% in patients with mBCC) with an estimated DOR exceeding one year in 83% of responders
- Libtayo is a mAb targeting the PD-1 on T-cells and acts by blocking the cancer cells from using the PD-1 pathway to suppress T-cell activation. Both the companies plan the regulatory submission of the therapy in 2020
Click here to read full press release/ article | Ref: Sanofi | Image: Money Control
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com